<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Icecure Medical — News on 6ix</title>
<link>https://6ix.com/company/icecure-medical</link>
<description>Latest news and press releases for Icecure Medical on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/icecure-medical" rel="self" type="application/rss+xml" />
<item>
<title>IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025</title>
<link>https://6ix.com/company/icecure-medical/news/icecure-participates-in-society-of-breast-imaging-symposium-2026-as-us-prosenser-revenue-increases-by-30percent-in-first-quarter-of-2026-compared-to-first-quarter-of-2025</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/icecure-participates-in-society-of-breast-imaging-symposium-2026-as-us-prosenser-revenue-increases-by-30percent-in-first-quarter-of-2026-compared-to-first-quarter-of-2025</guid>
<pubDate>Tue, 21 Apr 2026 12:30:00 GMT</pubDate>
<description>IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it expects to report U.S. revenue of ProSense® systems and cryoprobes increased more than 30% in the first quarter of 2026 compared the same period last year, based on preliminary, unaudited estimates.</description>
</item>
<item>
<title>IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement</title>
<link>https://6ix.com/company/icecure-medical/news/icecure-announces-pricing-of-dollar40-million-registered-direct-offering-and-concurrent-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/icecure-announces-pricing-of-dollar40-million-registered-direct-offering-and-concurrent-private-placement</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>CAESAREA, Israel, March 26, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of</description>
</item>
<item>
<title>IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates</title>
<link>https://6ix.com/company/icecure-medical/news/icecure-reports-positive-5-year-top-line-results-from-icesecret-kidney-cancer-cryoablation-study-894percent-and-839percent-recurrence-free-rates</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/icecure-reports-positive-5-year-top-line-results-from-icesecret-kidney-cancer-cryoablation-study-894percent-and-839percent-recurrence-free-rates</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors ≤3 cm and no prior kidney cancer; 83.9% recurrence-free rate for</description>
</item>
<item>
<title>IceCure Appoints Meir Peleg as Chief Financial Officer</title>
<link>https://6ix.com/company/icecure-medical/news/icecure-appoints-meir-peleg-as-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/icecure-appoints-meir-peleg-as-chief-financial-officer</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companiesIceCure intends to appoint Dr. Richard Fine as</description>
</item>
<item>
<title>IceCure Reports 2025 Full Year Financial & Operational Results</title>
<link>https://6ix.com/company/icecure-medical/news/icecure-reports-2025-full-year-financial-and-operational-results</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/icecure-reports-2025-full-year-financial-and-operational-results</guid>
<pubDate>Tue, 17 Mar 2026 12:30:00 GMT</pubDate>
<description>IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported record sales as of and for the twelve months ended December 31, 2025 as well as recent commercial and clinical updates.</description>
</item>
<item>
<title>U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer</title>
<link>https://6ix.com/company/icecure-medical/news/us-fda-approves-icecures-post-marketing-choice-study-for-prosenser-cryoablation-in-the-local-treatment-of-low-risk-breast-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/us-fda-approves-icecures-post-marketing-choice-study-for-prosenser-cryoablation-in-the-local-treatment-of-low-risk-breast-cancer</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>IceCure is engaged with leading medical institutions throughout the U.S. looking to participate in the post-market study with the FDA-cleared</description>
</item>
<item>
<title>IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026</title>
<link>https://6ix.com/company/icecure-medical/news/icecure-medical-to-report-2025-full-year-financial-and-operating-results-on-march-17-2026-8</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/icecure-medical-to-report-2025-full-year-financial-and-operating-results-on-march-17-2026-8</guid>
<pubDate>Tue, 10 Mar 2026 12:30:00 GMT</pubDate>
<description>IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2025 before the Nasdaq Stock Market opens on Tuesday, March 17, 2026. The Company will also discuss such results and other corporate developm</description>
</item>
<item>
<title>American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer</title>
<link>https://6ix.com/company/icecure-medical/news/american-society-of-breast-surgeons-asbrs-resource-guide-update-recommends-cryoablation-for-low-risk-breast-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/american-society-of-breast-surgeons-asbrs-resource-guide-update-recommends-cryoablation-for-low-risk-breast-cancer</guid>
<pubDate>Mon, 09 Mar 2026 12:30:00 GMT</pubDate>
<description>IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the American Society of Breast Surgeons' ("ASBrS") updated 2026 "Resource Guide on the Use of Transcutaneous and Percutaneous Ablation for the Treatment of Benign and Malignant Tumors of the Breast" recommends cryoablation as an option for selected patients with</description>
</item>
<item>
<title>IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas</title>
<link>https://6ix.com/company/icecure-medical/news/icecure-medical-reports-independent-study-published-in-plos-one-demonstrating-prosenser-cryoablation-safe-and-effective-in-treatment-of-breast-fibroadenomas</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/icecure-medical-reports-independent-study-published-in-plos-one-demonstrating-prosenser-cryoablation-safe-and-effective-in-treatment-of-breast-fibroadenomas</guid>
<pubDate>Mon, 02 Mar 2026 13:30:00 GMT</pubDate>
<description>IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the publication of an independent, investigator-initiated study evaluating ProSense® for the treatment of non-cancerous breast tumors, or fibroadenomas. The study, titled "Cryoablation for fibroadenoma with liquid nitrogen-based system: A retrospective analysis of prosp</description>
</item>
<item>
<title>Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board</title>
<link>https://6ix.com/company/icecure-medical/news/matricelf-ltd-tase-mtlf-appoints-ron-mayron-as-chairman-of-the-board-3</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/matricelf-ltd-tase-mtlf-appoints-ron-mayron-as-chairman-of-the-board-3</guid>
<pubDate>Fri, 27 Feb 2026 12:00:00 GMT</pubDate>
<description>Matricelf Ltd. (TASE: MTLF), a biotechnology company developing autologous engineered tissue therapies, today announced the appointment of Mr. Ron Mayron as Active Chairman of the Board of Directors. Mr. Mayron's appointment follows shareholder approval and submission of his formal Director Eligibility Declaration in accordance with the Israeli Companies Law.</description>
</item>
<item>
<title>IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026</title>
<link>https://6ix.com/company/icecure-medical/news/icecure-medical-successfully-completes-5-year-patient-follow-up-in-icesecret-kidney-cancer-cryoablation-study-final-analysis-expected-in-second-quarter-of-2026</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/icecure-medical-successfully-completes-5-year-patient-follow-up-in-icesecret-kidney-cancer-cryoablation-study-final-analysis-expected-in-second-quarter-of-2026</guid>
<pubDate>Mon, 23 Feb 2026 13:30:00 GMT</pubDate>
<description>IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the completion of its last patients' five-year follow up evaluation in its ICESECRET clinical trial of ProSense® for the treatment of small renal masses ("SRMs") in kidney cancer patients.</description>
</item>
<item>
<title>IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation</title>
<link>https://6ix.com/company/icecure-medical/news/icecure-announces-thomas-hospital-of-infirmary-health-installs-prosenser-becomes-first-hospital-in-alabama-to-offer-breast-cancer-cryoablation</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/icecure-announces-thomas-hospital-of-infirmary-health-installs-prosenser-becomes-first-hospital-in-alabama-to-offer-breast-cancer-cryoablation</guid>
<pubDate>Thu, 19 Feb 2026 13:30:00 GMT</pubDate>
<description>IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced Thomas Hospital of Fairhope, Alabama, part of the Infirmary Health network of hospitals, purchased and installed the ProSense® system, becoming the first facility in Alabama to offer breast cancer cryoablation. Dr. Katelin Holmes, a board-certified breast surgeon, Med</description>
</item>
<item>
<title>IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®</title>
<link>https://6ix.com/company/icecure-medical/news/icecure-announces-shero-imaging-first-133000526</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/icecure-announces-shero-imaging-first-133000526</guid>
<pubDate>Wed, 11 Feb 2026 13:30:00 GMT</pubDate>
<description>IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the most recent purchase and installation of the ProSense® system in the U.S. at St. Louis, Missouri based Shero Imaging, the first clinic in the state of Missouri to offer breast cancer cryoablation with ProSense®. Shero Imaging is dedicated to delivering exceptional</description>
</item>
<item>
<title>IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved</title>
<link>https://6ix.com/company/icecure-medical/news/icecure-announces-planned-departure-cfo-213000823</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/icecure-announces-planned-departure-cfo-213000823</guid>
<pubDate>Mon, 09 Feb 2026 21:30:00 GMT</pubDate>
<description>IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that after nearly a decade of service with IceCure, Chief Financial Officer Ronen Tsimerman has informed the Company of his decision to leave the Company to pursue new opportunities. The Company has initiated a search for a new Chief Financial Officer and has identifi</description>
</item>
<item>
<title>IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer</title>
<link>https://6ix.com/company/icecure-medical/news/icecure-celebrates-american-society-breast-133000693</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/icecure-celebrates-american-society-breast-133000693</guid>
<pubDate>Wed, 28 Jan 2026 13:30:00 GMT</pubDate>
<description>IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the American Society of Breast Surgeons (ASBrS) is in the final stage of updating its "Resource Guide on Transcutaneous and Percutaneous Treatment of Benign and Malignant Tumors of the Breast" which should include cryoablation for the local treatment of breast ca</description>
</item>
<item>
<title>IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales</title>
<link>https://6ix.com/company/icecure-medical/news/icecure-ceo-issues-letter-shareholders-133000454</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/icecure-ceo-issues-letter-shareholders-133000454</guid>
<pubDate>Mon, 12 Jan 2026 13:30:00 GMT</pubDate>
<description>IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today issued the following letter to shareholders from its Chief Executive Officer, Eyal Shamir.</description>
</item>
<item>
<title>IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer</title>
<link>https://6ix.com/company/icecure-medical/news/icecure-expected-report-record-fourth-133000676</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/icecure-expected-report-record-fourth-133000676</guid>
<pubDate>Wed, 17 Dec 2025 13:30:00 GMT</pubDate>
<description>IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, is expecting to report a significant increase in fourth quarter sales in North America compared to the same period last year. Based on currently available preliminary information, the increase in sales would represent record North American sales levels for the Company. The Company is e</description>
</item>
<item>
<title>IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting</title>
<link>https://6ix.com/company/icecure-medical/news/icecures-prosense-cryoablation-featured-4-133000193</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/icecures-prosense-cryoablation-featured-4-133000193</guid>
<pubDate>Wed, 10 Dec 2025 13:30:00 GMT</pubDate>
<description>IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that four abstracts featuring data from independent studies conducted by ProSense® users were accepted and presented at the Radiological Society of North America's ("RSNA") Annual Meeting, which took place from November 30 to December 4, 2025 in Chicago, Illinois.</description>
</item>
<item>
<title>IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes</title>
<link>https://6ix.com/company/icecure-medical/news/icecure-receives-notice-patent-allowance-133000071</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/icecure-receives-notice-patent-allowance-133000071</guid>
<pubDate>Fri, 05 Dec 2025 13:30:00 GMT</pubDate>
<description>IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it received a Notice of Allowance for a patent from the China National Intellectual Property Administration for its invention titled "Cryogen Flow Control" which relates to its next-generation XSense™ cryoablation system and probes.</description>
</item>
<item>
<title>IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025</title>
<link>https://6ix.com/company/icecure-medical/news/icecure-reports-financial-operational-results-133000521</link>
<guid isPermaLink="true">https://6ix.com/company/icecure-medical/news/icecure-reports-financial-operational-results-133000521</guid>
<pubDate>Wed, 19 Nov 2025 13:30:00 GMT</pubDate>
<description>IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported financial results as of and for the nine months ended September 30, 2025.</description>
</item>
</channel>
</rss>